Tirzepatide
Dual GIP/GLP-1 agonist for weight loss and blood sugar control. Clinically proven efficacy up to −22% of initial body weight.
What is Tirzepatide?
Tirzepatide (brand names Mounjaro, Zepbound) is an injectable medication and the first-in-class dual GIP and GLP-1 receptor agonist. Unlike semaglutide, it activates two hormonal pathways, delivering more pronounced weight loss effects.
Injection Protocol
Starting dose: 2.5 mg (2500 mcg) subcutaneously once weekly for 4 weeks.
Titration: Increase by 2.5 mg every 4 weeks as tolerated. Target dose: 5 to 15 mg weekly.
Injection sites: Abdomen, thigh, or upper arm. Rotate sites weekly.
Vial Reconstitution
Tirzepatide comes in 10 mg, 15 mg, or 30 mg vials. When reconstituting with 1 ml bacteriostatic water:
- 10 mg vial → 10 mg/ml → 2.5 mg = 0.25 ml = 25 units (U-100)
- 15 mg vial → 15 mg/ml → 5 mg = 0.33 ml = 33 units (U-100)
- 30 mg vial → 30 mg/ml → 7.5 mg = 0.25 ml = 25 units (U-100)
Storage
Unreconstituted vial: refrigerate (+2°C to +8°C). After reconstitution: refrigerate, use within 28 days. Do not freeze.
Important Warnings
- Do not use if you have pancreatitis or medullary thyroid cancer.
- Rapid weight loss can cause muscle mass loss — track protein intake carefully.
- May significantly reduce appetite — ensure adequate nutrition.
Peptides are often supplied as a dry powder and must be reconstituted with bacteriostatic water. After reconstitution, many manufacturers recommend using the solution within about 2 weeks, because peptide stability may gradually decrease over time. Marking a "new vial" helps track when a vial was first reconstituted and how long it has been in use.
Not sure if therapy is working?
Take a short effectiveness assessment — we'll check your food noise level and interpret the result.
Take assessmentOnce signed in, you can record injections and keep your injection history.
Sign inRapid weight loss burns muscle. Avoid Ozempic face by tracking your protein intake.
Check Protein Norm